Atavistik Bio Raises $120M Series B to Advance Precision Allosteric Therapies in Rare Disease and Oncology
Atavistik Bio, a Cambridge, Massachusetts–based biotechnology company focused on developing precision allosteric small-molecule therapeutics, has raised $120 million in a Series B financing to advance its clinical pipeline in rare diseases and oncology. The funding marks a significant step for the company as it moves its lead programs toward clinical development and expands the application of its proprietary discovery platform.
The Series B round was led by Nextech Invest and The Column Group, with participation from existing investor Lux Capital and new investor Regeneron Ventures. The company plans to use the proceeds to support clinical trials, strengthen its research and development capabilities, and further scale its operations as it advances multiple programs toward proof-of-concept milestones.
Founded in 2021, Atavistik Bio is built around a precision allostery approach to drug discovery. The company’s strategy centers on identifying and targeting cryptic allosteric binding sites on disease-relevant proteins, enabling the development of highly selective small molecules. This approach is designed to improve efficacy while minimizing the off-target toxicities often associated with less selective therapies. Atavistik Bio’s discovery efforts are powered by its Atavistik Metabolite-Protein Screening (AMPS™) platform, which combines experimental and computational methods to uncover novel regulatory mechanisms inspired by the body’s natural biology.
One of the company’s most advanced programs is an oral, allosteric AKT1-selective inhibitor being developed for the treatment of hereditary hemorrhagic telangiectasia (HHT), a rare genetic vascular disorder. HHT is characterized by abnormal blood vessel formation that can lead to frequent bleeding and serious complications, and there are currently no approved disease-modifying therapies. By selectively targeting AKT1, the isoform most directly implicated in HHT, Atavistik Bio aims to avoid the safety challenges seen with pan-AKT inhibitors and deliver a more tolerable long-term treatment option. The company expects this program to enter clinical trials in 2026.
In parallel, Atavistik Bio is advancing a mutant-selective inhibitor targeting JAK2 V617F, a key driver mutation in myeloproliferative neoplasms, a group of chronic blood cancers. Existing therapies for these conditions typically inhibit both mutant and normal JAK2 activity, which can limit effectiveness and cause side effects. Atavistik Bio’s approach is designed to selectively inhibit the disease-causing mutant while preserving normal signaling, with the goal of achieving deeper and more durable responses.
The Series B financing builds on earlier funding milestones. In 2023, the company raised $40 million to advance its precision allosteric therapeutic programs, with backing from The Column Group, Lux Capital, and Nextech Invest. That capital enabled Atavistik Bio to expand its discovery pipeline and progress its lead candidates toward preclinical development, laying the groundwork for the current round.
Atavistik Bio is led by an experienced management team with deep expertise in drug discovery and development. Under the leadership of CEO Bryan E. Stuart, the company has focused on building a strong scientific foundation while attracting long-term investors aligned with its vision for precision therapeutics. The addition of Regeneron Ventures to the investor syndicate further strengthens Atavistik Bio’s strategic network within the biotechnology and pharmaceutical ecosystem.
With the new funding in place, Atavistik Bio is positioned to accelerate its transition from a discovery-stage company to a clinical-stage organization. As it advances its lead programs and continues to apply its allosteric discovery platform to challenging targets, the company aims to deliver new treatment options for patients with serious diseases that currently have limited or inadequate therapies.
